Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst
Portfolio Pulse from Vandana Singh
ResMed Inc (NYSE:RMD) reported strong Q1 results with a 34% increase in EPS and 11% revenue growth, surpassing expectations. The company's fundamentals remain positive, supported by strong demand and operational excellence. Analyst William Blair rates the stock as Outperform.
October 25, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ResMed Inc reported a 34% increase in EPS and 11% revenue growth for Q1, beating expectations. The company's strong fundamentals and market position led to an Outperform rating by analyst William Blair.
ResMed's strong Q1 performance, with significant EPS and revenue growth, exceeded market expectations. The company's operational excellence and market position are highlighted by an Outperform rating from William Blair, indicating a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100